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Abstract 
Aim: Fluorescence-mediated tomography (FMT) holds potential for accelerating diagnostic and 
theranostic drug development. However, for proper quantitative fluorescence reconstruction, 
knowledge on optical scattering and absorption, which are highly heterogeneous in different 
(mouse) tissues, is required. We here describe methods to assess these parameters using 
co-registered micro Computed Tomography (µCT) data and nonlinear whole-animal absorption 
reconstruction, and evaluate their importance for assessment of the biodistribution and target site 
accumulation of fluorophore-labeled drug delivery systems. 
Methods: Besides phantoms with varying degrees of absorption, mice bearing A431 tumors were 
imaged 15 min and 48 h after i.v. injection of a fluorophore-labeled polymeric drug carrier 
(pHPMA-Dy750) using µCT-FMT. The outer shape of mice and a scattering map were derived 
using automated segmentation of the µCT data. Furthermore, a 3D absorption map was recon-
structed from the trans-illumination data. We determined the absorption of five interactively 
segmented regions (heart, liver, kidney, muscle, tumor). Since blood is the main near-infrared 
absorber in vivo, the absorption was also estimated from the relative blood volume (rBV), de-
termined by contrast-enhanced µCT. We compared the reconstructed absorption with the 
rBV-based values and analyzed the effect of using the absorption map on the fluorescence re-
construction. 
Results: Phantom experiments demonstrated that absorption reconstruction is possible and 
necessary for quantitative fluorescence reconstruction. In vivo, the reconstructed absorption 
showed high values in strongly blood-perfused organs such as the heart, liver and kidney. The 
absorption values correlated strongly with the rBV-based absorption values, confirming the ac-
curacy of the absorption reconstruction. Usage of homogenous absorption instead of the re-
constructed absorption map resulted in reduced values in the heart, liver and kidney, by factors of 
3.5, 2.1 and 1.4, respectively. For muscle and subcutaneous tumors, which have a much lower rBV 








Conclusion: Quantitative whole-animal absorption reconstruction is possible and can be vali-
dated in vivo using the rBV. Usage of an absorption map is important when quantitatively assessing 
the biodistribution of fluorescently labeled drugs and drug delivery systems, to avoid a systematic 
underestimation of fluorescence in strongly absorbing organs, such as the heart, liver and kidney. 
Key words: Fluorescence-mediated Tomography; Diffuse Optical Tomography; Micro-Computed 
Tomography; Multimodal Imaging; Drug delivery; Nanomedicine. 
Introduction 
Biodistribution assessment is an essential pro-
cedure during drug development to determine the 
off-target accumulation and the clearance rate [1–4]. 
To achieve this, organs and tissues are excised from 
lab mice at different time points and analyzed, which 
is laborious, expensive and involves the use of many 
mice. Theranostic drugs include a signaling moiety to 
allow the use of imaging devices to assess the locali-
zation of the probe in vivo. In this way, the mice can 
get scanned repeatedly, which reduces the number of 
required animals. Furthermore, data from the same 
subject is generated, which is statistically more pow-
erful. Nuclear methods, such as Positron emission 
tomography (PET), provide high accuracy and sensi-
tivity; however, the chemical synthesis is often com-
plicated and requires special equipment. As an alter-
native, theranostic concepts can be evaluated using 
preclinical optical imaging methods, which are fa-
vored because of their low cost, ease of use, high 
throughput and the absence of radioactivity [1,4]. 
Most frequently, planar optical reflectance imaging is 
used, which has the disadvantage of not being quan-
titative, surface weighted and almost unusable for 
longitudinal biodistribution studies. Fluores-
cence-mediated tomography (FMT) has the potential 
to overcome these limitations, since it is a tomo-
graphic and theoretically quantitative imaging 
method [5,6]. Furthermore, a rich variety of fluores-
cent probes is available, allowing imaging of proteol-
ysis, apoptosis, and angiogenesis among others 
[7–11], which can be applied to noninvasively monitor 
tumor progression, metastasis, and treatment re-
sponse [12–14]. Additionally, imaging of gene ex-
pression is possible using transgenic reporter mice or 
cells [5]. 
Fluorescence reconstruction requires modeling 
of the photon behavior inside the highly scattering 
and absorbing tissue. The Born normalization, which 
is commonly used for fluorescence reconstruction [6], 
compensates for incorrect assumptions of absorption 
and scattering for only some configurations as was 
shown in computer simulations and phantom studies 
[15–17]. However, accurate fluorescence reconstruc-
tion requires knowledge of the true absorption and 
scattering parameters [15,16,18]. The optical absorp-
tion in vivo (Table 1) is strongly determined by the 
presence of blood, because the absorption of hemo-
globin is much higher than other constituents in most 
tissues [19]. The relative blood volume (rBV) varies 
strongly in between different tissues, e.g. 2% for 
muscle, 30% for liver or 100% for pure blood. There-
fore, the absorption is highly heterogeneous in vivo, 
differing locally by orders of magnitude. Since probes 
are usually injected intravenously, the case of fluo-
rescence being co-localized to strongly absorbing re-
gions, such as blood, liver and kidneys, is highly rel-
evant, particularly for drugs with long blood circula-
tion and hepatic metabolization.  
 
Table 1: Absorption levels of blood at different wavelengths, 
corresponding to routinely used FMT channels. Values are based 
on measurements reported in [51]. Mixed blood assumes 80% 
venous and 20% arterial blood. 
Channel Venous Arterial Mixed 
635 nm 9.52 cm-1 3.19 cm-1 8.26 cm-1 
670 nm 5.59 cm-1 1.84 cm-1 4.84 cm-1 
745 nm 3.71 cm-1 2.61 cm-1 3.49 cm-1 
790 nm 4.26 cm-1 4.06 cm-1 4.23 cm-1 
 
 
For our study, we decided to use a commercially 
available and widely used FMT [2,10,20–23]. The im-
aging performance of FMT can get greatly enhanced 
by combining it with an anatomical modality, such as 
µCT [24]. The outer shape of the mouse is essential for 
reconstruction and can be derived from the µCT data 
[23,24]. A possibly automated segmentation of tissue 
classes [25] can be used in combination with 
class-specific absorption and scattering coefficients to 
derive absorption and scattering maps [7,16], similar 
as in PET-MR attenuation correction [26]. Unfortu-
nately, strongly absorbing regions such as large blood 
vessels, the liver, spleen or kidneys, are difficult to 
segment from native µCT scans due to the low 
soft-tissue contrast. Furthermore, the blood-perfusion 
and therefore the absorption are heterogeneous 
within organs and depend on the metabolic state and 
pathologies such as anemia. Fortunately, many tissue 
regions that differ in scattering, e.g. fat, skin, lung and 
bones, can be segmented from native µCT scans [25] 




and can be used to derive a scattering map using 
known tissue specific scattering coefficients [19].  
The applicability of FMT for in vivo biodistribu-
tion determination is not widely established. Initial 
results were reported using a standalone FMT [27], 
however, problems such as dislocated signal became 
apparent through the combination with µCT [2,22,23]. 
Furthermore, co-registered anatomical data is benefi-
cial for user-independent multi-organ analysis [2].  
The aim of our study is to improve the value of 
µCT-FMT for bio-distribution assessment. We derive 
a scattering map from the µCT-based segmentation 
and reconstruct a whole-animal absorption map from 
the FMT measurements. Our proposed concept of 
using a µCT blood-pool contrast agent enables vali-
dation of the whole-animal absorption reconstruction 
in vivo, for the first time, to the best of our knowledge. 
We show that usage of an absorption map is required 
to avoid systematic underestimation of fluorescence 
in strongly absorbing organs such as the heart, liver 
and kidney. Since these are relevant organs for many 
intravenously injected drugs, we believe that our 
method is an important step towards quantitative 
assessment of the bio-distribution of fluorescent di-
agnostic and theranostic drugs using µCT-FMT. 
Materials and Methods  
Approach 
After sequential µCT-FMT imaging, the µCT 
images were automatically segmented to find markers 
built into the mouse bed for automated fusion. Fur-
thermore, an automated segmentation of the outer 
shape and of several tissue regions for the scattering 
map was generated. The whole-animal absorption 
map was reconstructed by iterative minimization of 
the difference between predicted and measured exci-
tation boundary values. The absorption reconstruc-
tion and the effect on the fluorescence reconstruction 
were evaluated using phantom experiments. In vivo, 
the whole-animal absorption reconstruction was val-
idated using the µCT-derived relative blood volume, 
because the latter is known to essentially determine 
the absorption in many organs. In the next step, the 
influence of heterogeneous absorption and scattering 
maps on the fluorescence reconstruction was investi-
gated. For these experiments, a representative fluo-
rescent polymeric nanocarrier with prolonged circu-
lation time and passive tumor accumulation proper-
ties was used [2,20,22]. 
Hybrid µCT-FMT Imaging 
Phantoms and mice were imaged subsequently 
in µCT (Tomoscope DUO, CT-Imaging, Erlangen, 
Germany) and FMT (FMT2500, PerkinElmer, Wal-
tham, USA) [2,28]. The FMT uses a thermoelectrical-
ly-cooled back-illuminated 16 bit CCD camera 
(512x512 pixels, CCD size 12.3x12.3 mm). Whole-body 
FMT scans were acquired at excitation wavelength 
745 nm using 100-120 equidistant excitation positions 
(3 mm distance), covering the body from neck to tail. 
The control software of the FMT places the laser 
points so that all laser points are hitting the mouse to 
avoid damaging the camera. During scanning, the 
excitation laser power and exposure time are set as 
high as possible without oversaturating the detector. 
For a representative scan, this results in exposure 
times between 30 ms and 1278 ms (mean 180 ms, 
standard deviation 244 ms). The scanning duration 
was 5 minutes for µCT and around 15 minutes for 
FMT. For phantoms, 80-100 scan points were used. 
After the first FMT scan, the mouse bed, which tightly 
holds the mouse, was flipped vertically in the FMT to 
acquire a second scan, providing additional data for 
reconstruction. All experiments were performed us-
ing the same FMT and µCT. 
 
 
Figure 1: Segmentation used for the scattering map. Several tissue classes that differ 
in optical scattering were automatically segmented from the µCT data. Fixed scat-
tering coefficients were assigned to these tissue classes to generate a scattering map. 
(A) Transversal slice through the neck region, showing skin (orange), bones (cham-
pagne), fat (blue) and other tissue (light blue). (B) Slice through the lung (purple). (C) 
Slice through the hip and the tumor (arrow). (D) 3D rendering of the segmentation. 
 
Scattering Map 
To derive a scattering map for mouse bodies, 
several tissue regions (lungs, bones, fat, soft tissue, 
and skin) were automatically segmented based on the 
µCT data, similar to the approach in [25] (Figure 1). 
The algorithm roughly proceeds as follows: First, it 
segments the skin using a morphologic erosion oper-
ation of 2 voxels (voxel size 0.28 mm), starting from 
the outer shape of the mouse. Then the bones are 
segmented using a threshold (above 600 HU) and 
subsequent dilation (1 voxel). To segment the lung, 




another threshold (-200 HU) is applied. Subsequently, 
the lung is segmented as the largest connected com-
ponent of these voxels. Finally, the voxels below 0 HU 
are classified as fat. The scattering coefficients used 
for the tissue classes (Table 2) were derived from a 
recent review [19]. More precisely, we used the scat-
tering coefficients from table 2 in combination with 
formula 1 from [19]. 
 
Table 2: Scattering coefficients used for the scattering map (at 
wavelength 745nm). Values are based on measurements reported 
in [19]. 
Tissue Scattering 
Lung 20.5 cm-1 
Other 11.2 cm-1 
Bones 17.1 cm-1 
Skin 25.9 cm-1 




The absorption map was reconstructed using 
model based iterative image reconstruction [29]. The 
optical forward model was implemented using a fi-
nite difference mesh (mesh size 0.56mm) which ap-
proximates the diffusion equation [30]. This results in 
a sparse symmetric positive matrix 𝐴(µ𝑎), which de-
pends on the absorption map µ𝑎  and the fixed 
pre-determined scattering map. The 
three-dimensional absorption map µ𝑎 , treated as a 
flattened vector, was reconstructed by iteratively 
minimizing a differentiable nonlinear cost function f(µa) = ∑ (PkA(µa)−1sk − bk)2Kk=1  expressing the 
squared difference between predicted and measured 
boundary values for all 𝐾 source points. To compen-
sate for the high dynamic range of the measurements, 
the relative difference was used for bright measure-
ments above a pre-determined threshold. The source 
maps 𝑠𝑘 were modeled as Gaussian distributions. To 
decouple the degrees of freedom from the meshing 
accuracy, the absorption map was expressed in terms 
of nonnegative equidistant Gaussian basis functions. 
Boundary measurements 𝑏𝑘  were determined by 
projecting the pixels from the camera onto the mouse 
surface. 𝑃𝑘 is the linear operator that extracts the ob-
servable boundary values from the computed excita-
tion maps. The cost function 𝑓(µ𝑎)  was minimized 
with respect to the absorption map using the nonlin-
ear conjugate gradient method and the required gra-
dient computations were performed using algorith-
mic differentiation [31,32] with GPU-accelerated 
sparse vector and matrix operations [33]. The un-
known scale factor between source power and pixel 
intensities was calibrated using a phantom with 
known homogeneous scattering (8 cm-1) and negligi-
ble absorption (0.1 cm-1). Minimization of the cost 
function results in quantitative absorption values and 
further calibration, e.g. using a probe with known 
absorption, is not required.  
Fluorescence Reconstruction 
Using the scattering and absorption maps, the 
fluorescence distribution was reconstructed. This was 
performed by utilizing the normalized Born ratio and 
computing a dense weight matrix 𝑊  [4,7,24], from 
which the fluorescence distribution 𝑥  was recon-
structed by non-negative least squares minimization 
of 𝑓(𝑥) = ‖(𝑊𝑥 −𝑚)‖2 + 𝜆𝑥𝑇𝑥, where 𝜆𝑥𝑇𝑥 is a reg-
ularization term to avoid degenerate solutions. Fur-
thermore, the fluorescence was expressed in terms of 
nonnegative equidistant Gaussian basis functions 
(spacing 1.12 mm, standard deviation 1.12 mm). To 
solve the least squares system, GPU-accelerated mul-
tiplicative updates were used, a method with high 
performance and guaranteed non-negative solutions 
[34]. The same mesh size as for the absorption recon-
struction was used. Fluorescence was reconstructed 
using three configurations. First, heterogeneous ab-
sorption and heterogeneous scattering were used. 
Second, only the absorption map was replaced with a 
homogeneous absorption map (constant value of 0.3 
cm-1). Third, only the scattering map was replaced 
using homogeneous scattering (constant value of 11.2 
cm-1 from Table 1). For the in vivo experiments, the 
calibration factors were determined using phantom 
scans and a known amount of fluorescence.  
Phantom Experiments  
A block shaped FMT phantom (33x40x15 mm³, 
absorption 0.1 cm-1, scattering 8 cm-1), containing a 
cylindrical inclusion (diameter 3 mm, length 1 cm, 3 
mm below the surface), was scanned with varying 
concentrations of absorptive dye (E150, Wusitta, 
Sitzendorf, Germany) and a constant concentration of 
fluorescence (OsteoSense750, PerkinElmer, Waltham, 
USA, excitation peak 750 nm, emission peak 780 nm). 
To facilitate the segmentation of the inclusion in the 
µCT images, 5% CT contrast agent (Imeron 400, 
Bracco Imaging, Konstanz, Germany) was added. 
Additionally, computer simulations similar to [15] 
were performed to exclude a systematic error in the 
physical experiments. For these simulations, the same 
phantom shape and optical properties were used. The 
cylindrical inclusion was filled with constant fluores-
cence and varying absorption levels. Using the optical 
forward model, the measurable values on the surface 
were computed for all source points. Subsequently, 
the fluorescence was reconstructed using homoge-
neous and heterogeneous absorption maps. 
To assess the sensitivity of the FMT, we scanned 




the phantom with an increasingly diluted fluores-
cence concentration (OsteoSense750). The con-
trast-to-noise (CNR) ratio was determined to find the 
lowest concentration where the inclusion could be 
clearly distinguished from the background noise 
(CNR greater 4).  
Absorption of Blood 
Optical absorption of venous and arterial blood 
was determined for the four FMT channels of our 
device (Table 1) using measured absorption values of 
oxyhemoglobin and deoxyhemoglobin reported in 
[19,35]. We assumed a hemoglobin concentration in 
blood of 150 g/l, which is realistic for mice [36]. Fur-
thermore, we assumed venous and arterial oxygena-
tion levels of 70% and 98%, respectively. For mixed 
blood 80% venous and 20% arterial blood was as-
sumed. 
Animal Experiments 
All experimental procedures were approved by 
the local and national animal experiments ethics 
committee and conducted according to their regula-
tions. BALB/c nu/nu mice bearing a A431 tumor in 
the right hind limb were imaged by µCT-FMT directly 
and at 48 h after i.v. injection of a µCT blood pool 
contrast agent (50 µl, ExIA160XL, Binitio, Ottawa, 
USA), as well as 40 µl (2 nmol) of a prototypic pHP-
MA-based polymeric drug carrier labeled with the 
near-infrared fluorophore Dy750 (Dyomics GmbH, 
Jena, Germany) [2]. Five mice were imaged, but one 
mouse died before imaging at 48 h.  
Image Analysis 
Several organs (heart, liver, kidneys, muscle and 
tumor) were interactively segmented based purely on 
the µCT data using the Imalytics Preclinical Software 
(developed at ExMI, Aachen, Germany, in coopera-
tion with Philips Research, Aachen, Germany). The 
relative blood volume (rBV) of these organs was de-
termined based on the ratio between organ and blood 
enhancement created by the µCT blood pool agent 
[37,38]. For these organs, an average absorption value 
was estimated from the rBV, the absorption of mixed 
blood (Table 1) and assuming negligible absorption 
for unperfused tissue [19]. Using the organ segmenta-
tions, the average values of reconstructed absorption 
and reconstructed fluorescence concentration of the 
organs were determined. 
Statistical Analysis 
Pearson correlation analysis was used for the 
phantom experiments and to correlate the recon-
structed absorption with the rBV-based absorption of 
organs. Differences between fluorescence concentra-
tions of organs (reconstructed using heterogeneous 
and homogenous absorption) were shown using a 




To evaluate the absorption reconstruction under 
reproducible conditions, we used phantoms contain-
ing an inclusion with fluorescent and absorptive dyes. 
We imaged phantoms with identical fluorescence but 
varying absorption, which simulates the case of fluo-
rescence in highly or weakly blood-perfused, and 
therefore more or less optically absorbing, regions. 
The reconstructed absorption appeared in or at least 
near to the inclusion (Figure 2A,B) and correlated 
strongly with the dilution of the absorptive dye 
(R²=0.99, P<0.001), showing that the 3D absorption 
could be reconstructed quantitatively. Furthermore, 
the fluorescence concentration was reconstructed. 
First, the fluorescence was reconstructed assuming 
homogeneous absorption maps. Strong absorption 
caused significant underestimation of the recon-
structed fluorescence (Figure 2C,D). This effect was 
negligible for low absorption values (e.g. below 0.6 
cm-1), which confirms the results of previous simula-
tion studies [15,16], which ignored cases with stronger 
absorption. The underestimation of fluorescence did 
also occur when using the fluorescence reconstructed 
by the FMT system, which we registered with the µCT 
data, indicating that this phenomenon is not de-
pendent on our fluorescence reconstruction imple-
mentation. Our observed underestimation of fluores-
cence for strong co-localized absorption is explainable 
because the effect of absorption is stronger on the 
emission measurements than on the excitation meas-
urements (Figure 3). Therefore, these differences are 
not canceled completely by computing the ratio. The 
fluorescence reconstruction, which receives the ratio 
as input only, explains the measurements with low 
fluorescence, resulting in the observed underestima-
tion. By using the reconstructed heterogeneous ab-
sorption map for fluorescence reconstruction, the 
underestimation could be decreased (Figure 2D), in-
dicating that an absorption map is useful for quanti-
tative fluorescence reconstruction in realistic scenarios 
with high absorption. To show that these observations 
are not caused by experimental errors, we performed 
computer simulations, which resemble our lab ex-
periments with respect to the phantom shape and the 
absorption levels. In the simulations, virtual meas-
urements were created based on assumed fluores-
cence and absorption as described in [15]. Then the 
fluorescence was reconstructed assuming homoge-
nous and heterogeneous absorption maps. The results 




of these simulations confirmed our experimental re-
sults (Figure 2F), showing that low absorption values 
have little impact on the fluorescence reconstruction, 
however, that strong absorption causes significant 
underestimation of co-localized fluorescence. 
We also performed phantom experiments to de-
termine the sensitivity of the FMT, which showed 
that, using either reconstruction method, concentra-
tions down to 42 nM, i.e. 4.2 pmol inside the 100 µl 
region, could be distinguished from the background 
noise.  
Absorption in vivo  
To evaluate the absorption reconstruction in vivo, 
we analyzed the reconstructed absorption of organs 
and tumors in mice. For this analysis, several tissue 
regions (heart, liver, kidney, muscle, tumor) were 
segmented based on the µCT data. The reconstructed 
absorption values were high for heart (2.00 ± 0.32 
cm-1), liver (1.45 ± 0.11 cm-1) and kidney (1.04 ± 0.30 
cm-1), i.e. they were higher than 0.6 cm-1 which was 
the assumed maximum value in previous simulation 
studies [15,16]. It was relatively low for muscle (0.21 ± 
0.10 cm-1) and tumor (0.35 ± 0.22 cm-1). Strong absorp-
tion was also evident in the camera images acquired 
during the excitation pass, which showed almost 
complete extinction close to the heart. We also deter-
mined the relative blood volume (rBV) in these re-
gions using contrast enhanced µCT, which is possible, 
because the long circulating µCT contrast agent re-
sides in the blood immediately after injection [37,38]. 
The rBV was computed as the ratio between organ 
enhancement and blood enhancement, which were 
determined using the interactive segmentation. In the 
chosen regions, the relative blood volume dominates 
the near-infrared absorption [19], which enables val-
idation of the absorption reconstruction in vivo. We 
estimated the absorption from the rBV using the 
known absorption of blood (3.49 cm-1) at the used 
wavelength 745 nm (Table 1). The reconstructed ab-
sorption values were similar to the rBV-based ab-
sorption and correlation analysis showed a strong and 
significant correlation (R²=0.87, P<0.001, Figure 4). 
The slope of the regression line (slope=0.89) was rela-
tively close to 1, showing that the absorption could be 
reconstructed quantitatively. 
Fluorescence in vivo 
To apply µCT-FMT for biodistribution assess-
ment of a typical theranostic agent, we used a cus-
tomizable fluorescent nanopolymer suitable for im-
age-guided passive and active tumor-targeted drug 
delivery [2,20]. The mice were imaged directly and 
48h after i.v. injection. First, we compared the FMT 
reconstruction of the vendor with our newly imple-
mented fluorescence reconstruction. The FMT as-
sumes a block-shaped mouse, which causes artifacts 
such as dislocated signal outside the mouse, which 
become apparent after fusion with the µCT data 
(Figure 5). Our reconstruction, which uses the shape 
derived from the µCT for optical modeling, avoids 
these problems. Therefore, we only used our recon-
structions for analysis during this study. 
 
Figure 2: Phantom experiments. (A) Phantoms with a cylindrical inclusion filled with constant fluorescence and increasing absorptive dye concentrations. The reconstructed 
absorption appears correctly in the inclusion and is proportional to the absorptive dye concentration (B). (C) The reconstructed fluorescence appears in the inclusion but is 
suppressed by strong absorption when assuming homogeneous absorption, resulting in a strong negative correlation (D). Usage of the reconstructed heterogeneous absorption 
avoids this underestimation. Computer simulations using the same phantom shape (E) support the experimental results (F), showing that an absorption map is required to avoid 
underestimation of fluorescence in absorbing regions. 





Figure 3: Co-localized absorption and fluorescence. In this phantom, absorption and fluorescence are co-localized in a small cylindrical inclusion (arrow). The laser source is 
shown on the bottom. The absorption has a different effect on the excitation and emission measurements. For the excitation measurements (A), some photons pass through the 
absorption and some pass around the absorption, before reaching the surface where it is measured. For the emission measurements (B), all photon paths reaching the surface go 
through the absorbing region, where the fluorescence is located in this example. Therefore, the ratio of emission and excitation measurements does not cancel out the effect of 
heterogeneous absorption, which becomes apparent in the ratio images as seen from the camera (C). 
 
 
Figure 4: Absorption reconstruction in vivo. (A) Axial slices through the heart, liver and tumor (arrows) showing the absorption as red overlay. High absorption appears in the 
heart and the liver while the absorption in the tumor is low. (B) 3D rendering shows high absorption in the upper torso, where the heart and the liver reside. (C) Segmented 
regions (heart, liver, kidney, muscle and tumor) used to quantify the optical absorption. (D) Correlation of reconstructed organ absorption with the absorption determined from 





Figure 5: Improved fluorescence reconstruction using the shape. (A) The shape of the mouse is derived from the µCT data and used for accurate optical modeling and 
reconstruction. The mouse shape does not resemble a block which the standalone-FMT assumes for reconstruction. (B, C) The fused FMT reconstruction (left) is compared to 
the improved reconstruction (right) for transversal slices through liver and tumor, 48 h after injection of the nanopolymer. (B) Absence of the shape information results in 
erroneous signal in the air (arrow). Usage of the shape for reconstruction avoids this problem. (C) Fusion shows dislocated signal (arrow) above the tumor (green) which is 
corrected by using the shape for reconstruction. These examples show the importance of the shape information for fluorescence reconstruction. 
 
 





Figure 6: Effect of absorption on fluorescence in vivo. The effect of using homoge-
neous or heterogeneous absorption on the fluorescence reconstruction is analyzed 
15 min after i.v. injection of a long circulating fluorescence-labeled nanocarrier 
designed for passive tumor accumulation. (A) 3D renderings of reconstructed 
fluorescence distribution. Left: Reconstruction using homogeneous absorption. Right: 
Reconstruction using heterogeneous absorption. Both reconstructions use the shape 
information. High signal is expected in well-perfused organs such as heart, liver and 
kidneys shortly after i.v. injection. (B) Transversal slice through the heart (arrow). 
Only when using heterogeneous absorption (right), the expected strong signal in the 
heart is reconstructed. (C) Slice through the liver. (D) Fluorescence after injection is 
significantly (P<0.01) lower in strongly absorbing organs such as heart and liver when 
assuming homogenous absorption. 
 
 
Figure 7: Fluorescence in vivo 48h after injection. (A) 3D renderings of reconstructed 
fluorescence distribution. Left: Reconstruction using homogeneous absorption. Right: 
Reconstruction using heterogeneous absorption. High signal appears in the liver and 
tumor (arrows). (B) Transversal slice through the liver (arrow). (C) Slice through the 
subcutaneous tumor (arrow), 48 h after i.v. injection, showing high fluorescence 
concentration caused by passive probe accumulation. (D) Usage of the absorption 
map avoids underestimation of fluorescence in strongly absorbing organs such as 
heart and liver but hardly affects muscle and tumor (* indicates P<0.05). 
We reconstructed the fluorescence using the 
heterogeneous scattering and absorption maps. At the 
early time point where the agent mostly resides in the 
blood circulation, high fluorescence was detected at 
well-perfused organs such as heart, liver and kidneys 
(Figure 6). 48 h after injection, the fluorescence de-
creased in heart, liver, kidney and muscle (Figure 7). 
The signal in the tumor increased significantly 
(P<0.05) from 40 ± 10 nM to 144 ± 59 nM, due to the 
expected passive accumulation through leaky blood 
vessels (Figure 7). To assess the effect of the hetero-
geneous absorption map, the fluorescence was also 
reconstructed using homogenous absorption. The 
same heterogeneous scattering map was used, which 
had been derived from the µCT-based segmentation 
and tissue specific scattering coefficients (Table 2). 




The fluorescence in the tumor increased from 43 ± 12 
nM to 139 ± 49 nM, P<0.05, similar to the absorp-
tion-corrected method. Therefore, the absorption 
correction only had a minor effect on the tumor. In 
strongly absorbing organs, such as heart, liver and 
kidney, a systematic difference was observed, how-
ever. When assuming homogenous absorption, the 
reconstructed fluorescence was reduced by a factor 
3.5 ± 0.6 for the heart, by 2.1 ± 0.3 in the liver and by 
1.4 ± 0.4 in the kidney. These differences were signif-
icant for heart and liver but not for kidney, muscle 
and tumor. The suppressed liver signal caused a sig-
nificantly (P<0.05) higher tumor to liver ratio (0.93 ± 
0.37 vs. 0.47 ± 0.24 using absorption correction), 
showing that the assumption of homogenous absorp-
tion causes overoptimistic estimates of the tu-
mor-to-liver ratio. 
Next to analyzing the influence of the absorption 
map on the fluorescence quantification, we also in-
vestigated the effect of different scattering maps for 
fluorescence reconstruction. Compared to absorption, 
usage of a scattering map had less of an effect for 
whole-animal scans (Figure 8). This is reasonable, 
because the absorption varies much more between 
organs due to the strongly varying relative blood 
volume. 
Discussion 
The aim of our study was to improve the ap-
plicability of FMT for quantitative bio-distribution 
assessment. To this end, we investigated the necessity 
of absorption modeling for fluorescence reconstruc-
tion. Phantom and in vivo experiments showed that 
the spatial absorption map can be reconstructed 
quantitatively, and its usage for fluorescence recon-
struction is essential to avoid underestimation of flu-
orescence in strongly absorbing regions. Underesti-
mation of fluorescence in absorbing regions might 
sound obvious, but it is not, since the normalized born 
ratio is intended to and capable of correcting incorrect 
absorption modeling. This was shown in computer 
simulations and phantom studies for cases of low 
absorption or when the absorption is distant to the 
fluorescence [15–17]. However, this seems not to be 
true for co-localization of fluorescence and strong 
absorption.  
A reasonable absorption map is difficult to de-
rive from native µCT scans because liver, spleen and 
kidney are difficult to be segmented automatically. 
Blood vessels, which strongly determine the absorp-
tion, are even more difficult to be segmented, because 
blood is hardly distinguishable from other soft tissues 
such as muscle. Therefore, we used the µCT data to 
estimate a scattering map using automated segmen-
tation of tissue regions such as bones, fat, and the 
lung. Instead of relying on an error-prone automated 
or manual segmentation to derive the absorption 
map, we reconstructed the absorption map from the 
optical raw data. It is difficult to validate the absorp-
tion reconstruction by analyzing excised organs, be-
cause the blood coagulates, deoxygenates or flows out 
of the organs. Therefore, we validated the absorption 
reconstruction in vivo using the µCT-derived relative 
blood volume, which is applicable because blood is 
the dominant absorber in these organs [19,35], and 
oxygenated and deoxygenated hemoglobin have sim-
ilar absorption at the chosen wavelength (Table 1). An 
alternative method to derive an absorption map could 
be to use an iodine-based µCT blood pool contrast 
agent in combination with dual energy µCT imaging 
for blood vessel segmentation [39]. However, for rou-
tine µCT-FMT imaging, the use of µCT contrast agent 
is problematic for reasons of handling and toxicity. 
Furthermore, a steady state of µCT contrast en-
hancement is hardly achievable for longitudinal im-
aging, because the µCT contrast agent has its own 
dynamic bio-distribution.  
 
 
Figure 8: Effect of scattering map. The effect of using homogenous and heterogeneous scattering on the fluorescence reconstruction was compared. The heterogeneous 
scattering map is derived from the µCT-based segmentation. Both methods perform absorption reconstruction. (A) Fluorescence 15 min after injection. (B) Fluorescence 48h 
after injection. Assuming homogenous scattering results in slight overestimation of fluorescence in all regions (* indicates P<0.05 and ** indicates P<0.01). 
 




Absorption reconstruction is a nonlinear prob-
lem, particularly for strong absorption [40], requiring 
a computationally demanding iterative method 
[29,41]. Due to the computational load, previous 
studies were often restricted to 2D configurations [42] 
or small fields-of-view [40]. To perform 3D recon-
structions of whole animals, we compute the gradi-
ents using algorithmic differentiation [32] with 
GPU-accelerated sparse vector and matrix operations 
[33], where the derivatives are propagated backwards 
through a linear solver [31] at each iteration. This ap-
proach could be extended to use multispectral data or 
to include the emission channel to potentially allow 
reconstruction of absorption and scattering which is 
not generally possible using a single 
trans-illumination channel [43]. The convergence of 
the nonlinear reconstruction could be improved using 
Quasi-Newton methods [42] compared to the robust 
and simple nonlinear conjugate gradient method 
which we currently use. 
In our study, we performed whole-body scans 
resulting in coarse laser source points (3 mm dis-
tance), limiting the achievable resolution of recon-
structed absorption and fluorescence. This could be 
improved by increasing the number of measurement 
points (and the measurement time), by restricting 
imaging to a smaller part of the body or by using the 
segmentation for regularization for the fluorescence 
reconstruction [7,23]. To increase the number of 
measurements, we combined up and down scans into 
one reconstruction, which can be further increased 
using 360° systems [24]. However, the benefit of 360° 
is not as important as in computed tomography where 
real projections are acquired, because for diffuse op-
tical imaging only viewing-angle-independent surface 
measurements are obtained. Our approach can be 
used with other continuous wave FMT systems as 
long as µCT data is available to derive the outer shape 
and a scattering map. While reconstruction of absorp-
tion and scattering may be feasible under certain 
conditions [44], we derived the scattering map 
through a segmentation, which reduces the number of 
free parameters and also avoids the issue of ambigu-
ity [43]. Our segmentation-based scattering map is not 
perfect, however, because some regions, e.g. stomach 
contents, are omitted, and, in reality, the scattering is 
not homogeneous within the segmented regions. 
Nevertheless, we show that using heterogeneous 
scattering maps has less of an effect for fluorescence 
reconstruction than using heterogeneous absorption 
maps. While this differs from previous results [15], 
our results are explainable because for whole-animal 
scans the absorption is much stronger and varies 
much more than anticipated in these computer simu-
lations.  
Currently, we can only show that the absorption 
map makes a relevant difference for the fluorescence 
reconstruction in vivo. To achieve a quantitative vali-
dation of the fluorescence reconstruction in vivo, du-
al-tracer imaging (nuclear and fluorescent) would be a 
good solution [45–47]. Furthermore, the fluorescence 
signal in the heart appears lower than expected when 
compared to the liver. One reason may be that strong 
absorption leads to a loss of many measurement 
points close to the heart, because the measured exci-
tation light has to be well above the noise level to be 
used for the normalizing ratio [48]. This could be 
overcome by increasing the exposure time in combi-
nation with high dynamic range imaging. Further-
more, the strong absorption in some regions may jus-
tify use of the more complex radiative transfer equa-
tion (RTE) instead of the diffusion equation [49], be-
cause the latter assumes that absorption is well below 
scattering. Photoacoustic imaging could be an alter-
native modality to compute an absorption map, if 
quantitative reconstruction issues and problems with 
the special acoustic properties of lungs and bones can 
be resolved [50]. Not only for fluorescence recon-
struction, but also for other optical imaging tech-
niques, e.g. quantitative bioluminescence reconstruc-
tion [48], the availability of a whole-animal absorption 
map could be useful. Furthermore, by using multi-
spectral imaging, i.e. absorption reconstruction in 
several wavelengths, the tissue oxygenation could be 
determined. 
We found that the reconstructed fluorescence in 
the subcutaneous tumor is hardly affected by absorp-
tion modeling, which is in line with previously re-
ported results where strong absorption was posi-
tioned around the fluorescence [17]. For experiments 
with tumors that contain hemorrhages or melanin an 
absorption map should be used, however. Further-
more, the phenomenon of fluorescence underestima-
tion in the liver may cause overoptimistic estimates 
for the tumor-to-liver ratio, which can be used to as-
sess the efficacy of tumor targeted drugs [2], by 
roughly a factor two. Consequently, proper absorp-
tion modeling should be used for such studies, be-
cause otherwise, it might lead to inaccurate conclu-
sions. Compared to the other available FMT channels, 
the channel at 745 nm has lowest absorption for mixed 
blood (Table 1) and, therefore, the observed effects 
should be even stronger in the other channels. 
In conclusion, our results indicate that the ab-
sorption map can be reconstructed quantitatively 
from the optical raw data when assuming that an ap-
proximate scattering map is available. Our novel ap-
proach of using contrast-enhanced µCT to determine 
the relative blood volume is an essential step to eval-
uate the absorption reconstruction in vivo. We show 




that an absorption map is required to avoid strong 
and systematic underestimation of fluorescence in 
highly absorbing regions, such as the heart, liver and 
kidneys. Therefore, absorption should be recon-
structed and used when the bio-distribution is to be 
determined quantitatively using FMT. Since 
bio-distribution assessment is necessary to character-
ize the excretion pathways and to exclude unwanted 
accumulation sites, we believe that our results are an 
important step towards establishing µCT-FMT as a 
valuable tool for diagnostic and theranostic drug de-
velopment. 
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FMT: Fluorescence-mediated Tomography; µCT: 
Micro-Computed Tomography; rBV: relative Blood 
Volume; CW: Continuous Wave. 
Acknowledgements 
We thank Marek Weiler for performing the 
phantom experiments. This work was supported by 
the European Research Council (ERC Starting Grant 
309495: NeoNaNo), the European Commission (FP7: 
COST-Action TD1004: Nanotheragnostics), the Ger-
man Federal State of North Rhine Westphalia (NRW; 
High-Tech.NRW/EU-Ziel 2-Programm (EFRE); For-
SaTum), the German Research Foundation (DFG: 
La2937/1-2), RWTH Aachen University (I3TM Seed 
Fund) and Philips Research (Aachen, Germany). 
Competing Interests 
Felix Gremse is founder and owner of Grem-
se-IT, a startup company that offers software and ser-
vices for medical image analysis in cooperation with 
Philips and the Department for Experimental Molec-
ular Imaging of the RWTH Aachen University. 
References 
1.  Baker M. Whole-animal imaging: The whole picture. Nature. 2010; 463(7283): 
977–80.  
2.  Kunjachan S, Gremse F, Theek B, et al. Noninvasive optical imaging of nano-
medicine biodistribution. ACS Nano. 2013; 7(1): 252–62.  
3.  Licha K, Olbrich C. Optical imaging in drug discovery and diagnostic appli-
cations. Adv Drug Deliv Rev. 2005; 57(8): 1087–108.  
4.  Stuker F, Ripoll J, Rudin M. Fluorescence Molecular Tomography: Principles 
and Potential for Pharmaceutical Research. Pharmaceutics. 2011; 3(2): 229–74.  
5.  Ntziachristos V. Fluorescence molecular imaging. Annu Rev Biomed Eng. 
2006; 8: 1–33.  
6.  Ntziachristos V, Weissleder R. Experimental three-dimensional fluorescence 
reconstruction of diffuse media by use of a normalized Born approximation. 
Opt Lett. 2001; 26(12): 893–5.  
7.  Ale A, Ermolayev V, Herzog E, et al. FMT-XCT: in vivo animal studies with 
hybrid fluorescence molecular tomography-X-ray computed tomography. Nat 
Methods. 2012; 9(9): 615–20.  
8.  Eisenblätter M, Ehrchen J, Varga G, et al. In vivo optical imaging of cellular 
inflammatory response in granuloma formation using fluorescence-labeled 
macrophages. J Nucl Med. 2009; 50(10): 1676–82.  
9.  Lederle W, Arns S, Rix A, et al. Failure of annexin-based apoptosis imaging in 
the assessment of antiangiogenic therapy effects. EJNMMI Res. 2011; 1: 26.  
10.  Nahrendorf M, Waterman P, Thurber G, et al. Hybrid in vivo FMT-CT imag-
ing of protease activity in atherosclerosis with customized nanosensors. Arte-
rioscler Thromb Vasc Biol. 2009; 29(10): 1444–51.  
11.  Rao J, Dragulescu-Andrasi A, Yao H. Fluorescence imaging in vivo: recent 
advances. Curr Opin Biotechnol. 2007; 18(1): 17–25.  
12.  Al Rawashdeh W, Arns S, Gremse F, et al. Optical tomography of 
MMP-activity allows a sensitive non-invasive characterization of the inva-
siveness and angiogenesis of SCC-xenografts. Neoplasia. 2014; 16(3): 235–46.  
13.  Kaijzel EL, van der Pluijm G, Löwik CWGM. Whole-body optical imaging in 
animal models to assess cancer development and progression. Clin Cancer 
Res. 2007; 13(12): 3490–7.  
14.  Li R, Zheng K, Chen Z, et al. A Novel Tumor Targeting Drug Carrier for 
Optical Imaging and Therapy. Theranostics. 2014; 4(6): 642–59.  
15.  Abascal JFP-J, Aguirre J, Chamorro-Servent J, et al. Influence of absorption 
and scattering on the quantification of fluorescence diffuse optical tomogra-
phy using normalized data. J Biomed Opt. 2012; 17(3): 036013.  
16.  Hyde D, Schulz R, Brooks D, et al. Performance dependence of hybrid x-ray 
computed tomography/fluorescence molecular tomography on the optical 
forward problem. J Opt Soc Am A Opt Image Sci Vis. 2009; 26(4): 919–23.  
17.  Soubret A, Ripoll J, Ntziachristos V. Accuracy of fluorescent tomography in 
the presence of heterogeneities: study of the normalized Born ratio. IEEE Trans 
Med Imaging. 2005; 24(10): 1377–86.  
18.  Patwardhan SV, Culver JP. Quantitative diffuse optical tomography for small 
animals using an ultrafast gated image intensifier. J Biomed Opt. 2008; 13(1): 
011009.  
19.  Jacques SL. Optical properties of biological tissues: a review. Phys Med Biol. 
2013; 58(11): R37.  
20.  Kunjachan S, Pola R, Gremse F, et al. Passive versus Active Tumor Targeting 
Using RGD- and NGR-Modified Polymeric Nanomedicines. Nano Lett. 2014; 
14(2): 972–81.  
21.  Schober A, Nazari-Jahantigh M, Wei Y, et al. MicroRNA-126-5p promotes 
endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat 
Med. 2014; 20(4): 368–76.  
22.  Theek B, Gremse F, Kunjachan S, et al. Characterizing EPR-mediated passive 
drug targeting using contrast-enhanced functional ultrasound imaging. J 
Control Release. 2014;(182): 83–9.  
23.  Radrich K, Ale A, Ermolayev V, et al. Improving limited-projection-angle 
fluorescence molecular tomography using a co-registered x-ray computed 
tomography scan. J Biomed Opt. 2012; 17(12): 126011.  
24.  Schulz RB, Ale A, Sarantopoulos A, et al. Hybrid system for simultaneous 
fluorescence and x-ray computed tomography. IEEE Trans Med Imaging. 
2010; 29(2): 465–73.  
25.  Freyer M, Ale A, Schulz RB, et al. Fast automatic segmentation of anatomical 
structures in x-ray computed tomography images to improve fluorescence 
molecular tomography reconstruction. J Biomed Opt. 2010; 15(3): 036006.  
26.  Keereman V, Mollet P, Berker Y, et al. Challenges and current methods for 
attenuation correction in PET/MR. MAGMA. 2013; 26(1): 81–98.  
27.  Vasquez KO, Casavant C, Peterson JD. Quantitative Whole Body Biodistribu-
tion of Fluorescent-Labeled Agents by Non-Invasive Tomographic Imaging. 
PLoS ONE. 2011; 6(6): e20594.  
28.  Doleschel D, Mundigl O, Wessner A, et al. Targeted near-infrared imaging of 
the erythropoietin receptor in human lung cancer xenografts. J Nucl Med. 
2012; 53(2): 304–11.  
29.  Hielscher AH. Optical tomographic imaging of small animals. Curr Opin 
Biotechnol. 2005; 16(1): 79–88.  
30.  Sevick-Muraca EM, Rasmussen JC. Molecular imaging with optics: primer and 
case for near-infrared fluorescence techniques in personalized medicine. J 
Biomed Opt. 2008; 13(4): 041303.  
31.  Davies AJ, Christianson DB, Dixon LCW, et al. Reverse differentiation and the 
inverse diffusion problem. Adv Eng Softw. 1997; 28(4): 217–21.  
32.  Naumann U. The Art of Differentiating Computer Programs: An Introduction 
to Algorithmic Differentiation. Philadelphia, PA, USA: SIAM. 2012:358p.  
33.  Bell N, Dalton S, Olson LN. Exposing Fine-Grained Parallelism in Algebraic 
Multigrid Methods. SIAM J Sci Comput. 2012; 34(4): C123–C152.  
34.  Lin C-J. On the Convergence of Multiplicative Update Algorithms for 
Nonnegative Matrix Factorization. IEEE Trans Neural Netw. 2007; 18(6): 1589 
–1596.  
35.  Cheong W-F, Prahl SA, Welch AJ. A review of the optical properties of bio-
logical tissues. IEEE J Quantum Electron. 1990; 26(12): 2166–85.  
36.  Goulden F, Warren FL. The Hemoglobin Content of the Blood of Mice of the 
RIII and CBA Strains. Cancer Res. 1944; 4(7): 421–4.  
37.  Ehling J, Bartneck M, Wei X, et al. CCL2-dependent infiltrating macrophages 
promote angiogenesis in progressive liver fibrosis. Gut. 2014.  
38.  Ehling J, Theek B, Gremse F, et al. Micro-CT imaging of tumor angiogenesis: 
quantitative measures describing micromorphology and vascularization. Am J 
Pathol. 2014; 184(2): 431–41.  
39.  Gremse F, Grouls C, Palmowski M, et al. Virtual Elastic Sphere Processing 
Enables Reproducible Quantification of Vessel Stenosis at CT and MR Angi-
ography. Radiology. 2011; 260: 709–17.  
40.  Arridge SR, Dorn O, Kolehmainen V, et al. Parameter and structure recon-
struction in optical tomography. J Phys: Conf Ser. 2008; 135(1): 012001.  
41.  Arridge SR, Schotland JC. Optical tomography: forward and inverse prob-
lems. Inverse Probl. 2009; 25(12): 123010.  
42.  Klose AD, Hielscher AH. Quasi-Newton methods in optical tomographic 
image reconstruction. Inverse Probl. 2003; 19(2): 387.  
43.  Arridge SR, Lionheart WRB. Nonuniqueness in diffusion-based optical to-
mography. Opt Lett. 1998; 23(11): 882–4.  
44.  Harrach B. Simultaneous determination of the diffusion and absorption 
coefficient from boundary data. Inverse Probl Imaging. 2012; 6(4): 663–79.  




45.  Culver J, Akers W, Achilefu S. Multimodality Molecular Imaging with Com-
bined Optical and SPECT/PET Modalities. J Nucl Med. 2008; 49(2): 169–72.  
46.  Garofalakis A, Dubois A, Kuhnast B, et al. In vivo validation of free-space 
fluorescence tomography using nuclear imaging. Opt Lett. 2010; 35(18): 
3024–6.  
47.  Xing Y, Zhao J, Conti PS, et al. Radiolabeled Nanoparticles for Multimodality 
Tumor Imaging. Theranostics. 2014; 4(3): 290–306.  
48.  Ntziachristos V, Ripoll J, Wang LV, et al. Looking and listening to light: the 
evolution of whole-body photonic imaging. Nat Biotechnol. 2005; 23(3): 
313–20.  
49.  Arridge SR. Optical tomography in medical imaging. Inverse Probl. 1999; 
15(2): R41.  
50.  Lutzweiler C, Razansky D. Optoacoustic Imaging and Tomography: Recon-
struction Approaches and Outstanding Challenges in Image Performance and 
Quantification. Sensors. 2013; 13(6): 7345–84.  
51.  [Internet] Prahl S. Optical absorption of hemoglobin. http://omlc.ogi.edu/ 
spectra/hemoglobin.   
